Key Trends Shaping the Future Intravenous Immunoglobulin Market From 2025-2034: GC Pharma Launches Innovative Liquid Immune Globulin Formulation For Immunodeficiency Treatment

What combination of drivers is leading to accelerated growth in the intravenous immunoglobulin market?
The escalation in the number of elderly individuals is anticipated to propel the advancement of the intravenous immunoglobulin market. The term elderly population is used to describe those aged 65 and above. With age, the immune system weakens and the body's supply of antibodies decreases, necessitating the need for immunoglobulins. This subsequently elevates the demand for intravenous immunoglobulins, thereby boosting the intravenous immunoglobulin market. For example, data obtained by the Population Reference Bureau, a Kenya-based nonprofit organization, in January 2024 stipulated that the American population aged 65 and above is projected to increase from 58 million in 2022 to 82 million by 2050, marking a 47% growth. The percentage of this age group within the overall population is also estimated to escalate from 17% to 23% over the same period. Consequently, the expanding elderly population is set to spur the growth of the intravenous immunoglobulin market.

Get Your Intravenous Immunoglobulin Market Report Here:
https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

What is the projected compound annual growth rate (CAGR) of the intravenous immunoglobulin market from 2025 to 2034, and what factors influence it?
The market for intravenous immunoglobulin has seen robust growth in the past few years. The market is projected to experience an increase from $14.66 billion in 2024 to $15.72 billion in 2025, resulting in a compound annual growth rate (CAGR) of 7.2%. The strong historic growth has been influenced by factors such as the treatment of primary immunodeficiency disorders, handling of neurological disorders, the escalation of the aged population, advancements in the technology for plasma fractionation, the expanded applications in neurology, treatments for infectious diseases, and care of pediatric immunodeficiency.

Expectations are high for robust growth in the intravenous immunoglobulin market in the forthcoming years. It is projected to expand to $22.01 billion in 2029, with a compound annual growth rate (CAGR) of 8.8%. This growth during the forecasted period is attributed to factors such as the rising cases of autoimmune diseases, continuous research in immunology, an increase in healthcare spending, a surge in cancer cases, advancements in immunoglobulin products, and the introduction of personalized medicinal practices. The primary trends driving this growth forecast include the treatment of primary immunodeficiency disorders (PIDD), rapid advancements in technology, strategic collaborations and partnerships, improved manufacturing processes, emerging indications in neurology, usage in hematology, and advances in immunotherapy.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

How are the latest trends influencing the growth of the intravenous immunoglobulin market?
The increasing trend of product innovation is becoming more prevalent in the intravenous immunoglobulin market. Major market players are centering their strategy around the development of new products, like liquid immune globulin formulations, for treating immunodeficiency diseases and maintaining their market presence. For example, in December 2023, GC Pharma, a pharmaceutical company based in South Korea, introduced Alyglo, approved by the US Food and Drug Administration (FDA). Alyglo is a sterile, 10% immunoglobulin G (IgG) liquid formulation, which offers 100 mg/mL of protein, and a minimum of 96% originates from human IgG derived from collective human plasma. The drug is specifically meant for adults 17 years and older suffering from primary humoral immunodeficiency (PI). This includes illnesses like congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

What are the major segments of the intravenous immunoglobulin market and their role in driving growth?
The intravenous immunoglobulin market covered in this report is segmented -

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications
4) By End-User: Hospitals, Clinics, Home Care

Subsegments:
1) By Immunoglobulin G (IgG): Normal IgG, Specific IgG
2) By Immunoglobulin M (IgM): Normal IgM, Specific IgM
3) By Immunoglobulin A (IgA): Normal IgA, Specific IgA
4) By Immunoglobulin E (IgE): Normal IgE, Specific IgE
5) By Immunoglobulin D (IgD): Normal IgD, Specific IgD

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8538

Which regions are key players in the growth of the intravenous immunoglobulin market?
North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the intravenous immunoglobulin market?
Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

What Is Covered In The Intravenous Immunoglobulin Global Market Report?

• Market Size Forecast: Examine the intravenous immunoglobulin market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the intravenous immunoglobulin market for a structured understanding.
• Key Players Overview: Analyze major players in the intravenous immunoglobulin market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the intravenous immunoglobulin market.
• Segment Contributions: Evaluate how different segments drive overall growth in the intravenous immunoglobulin market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the intravenous immunoglobulin market.
• Industry Challenges: Identify potential risks and obstacles affecting the intravenous immunoglobulin market.
• Competitive Landscape: Review strategic developments in the intravenous immunoglobulin market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.